Clinical Development Work to Ensure Patient Safety: The Critical Final Step of New Drug Development Clinical Development Work to Ensure Patient Safety: The Critical Final Step of New Drug Development

Clinical development is responsible for conducting clinical trials that administer investigational drugs to study participants in order to evaluate their safety and efficacy.

When a pharmaceutical company submits an application for marketing approval to the relevant regulatory authority, the data obtained during clinical trials serves as evidence regarding a drug's safety and efficacy.

Santen’s multi-stage R&D process involves various departments within the company. Compound Discovery and Development identifies compounds that will serve as the active ingredients in drugs; Formulation designs a finished drug product based on the active pharmaceutical ingredient (API) for use by patients; Non-Clinical Development uses cell cultures and animals to evaluate drug safety and efficacy; and Regulatory Affairs handles various procedures, including regulatory filings. Clinical Development plays a pivotal role in the final stage of the R&D process, ensuring that all of this work leads to regulatory approval and ultimately brings safe and effective medicines to market.

Clinical trials are conducted through a network of participating medical institutions. A drug that has been determined to be suitable for treating a particular disease based on the results of non-clinical studies conducted in a laboratory will be administered to participants in a clinical trial. Participants typically include healthy individuals and patients recruited through public recruitment, as well as patients who have consented to participate in clinical trials at participating medical institutions. All participants receive a detailed explanation of the trial and provide their informed consent. Clinical data are then collected after administration to verify the drug’s efficacy and evaluate its safety.

A clinical trial begins with a small number of initial participants and we continuously assess the drug’s safety while gradually expanding the study population. Safety and efficacy are often evaluated by comparing outcomes from use of the investigational drug with those resulting from use of existing drugs or a placebo*.

If the data collected during the clinical trial stage is not sufficiently reliable, then regulatory authorities will not approve the drug. Furthermore, use of clinical data that has not been subjected to thorough analysis could pose a health risk for patients. Clinical Development’s mission is to prevent this from happening, and we do this by ensuring that clinical trials are conducted properly.

I have been involved in clinical development at Santen for more than 20 years. My experience relates chiefly to the day-to-day process of launching and conducting clinical trials, and I currently serve as a clinical manager, overseeing the management of clinical trials conducted in Japan and across the Asia-Pacific region.

The primary responsibility of a clinical manager is to plan and execute clinical trials in collaboration with the drug development and non-clinical development teams. Since clinical development is conducted on a global scale, trials intended for approval and distribution outside of Japan must be designed in accordance with the regulatory requirements and standards of each region. This means that I have frequent opportunities to communicate in English with overseas staff who are well-versed in local regulations and other relevant matters.

Each trial is conducted by a monitor (a staff member responsible for managing and overseeing the trial’s progress), who visits the participating medical institutions and coordinates with doctors and medical staff. Meanwhile, the clinical manager reviews the data submitted by the monitor, makes decisions when unexpected issues arise, and coordinates the flow of information. Another important task is compiling the data required for regulatory submission after the trial has concluded.

The detailed planning that takes place prior to the start of a clinical trial, and when responding to unforeseen circumstances that may arise after the trial has begun.

Numerous factors need to be considered before a clinical trial begins. These include how to recruit patients and how many participants to include; the number of study materials to be delivered; how to store them at the hospital; the dosage and administration of medications; and the testing methods and evaluation criteria. Taken individually each of these decisions may seem minor, but all of them directly impact the patient burden, the safety of the trial, and the reliability of the data obtained.

Increasing the number of tests can yield more accurate data, but it also places a greater burden on healthcare providers. On the other hand, if the number of tests is too small, then getting reliable data will be impossible. And while short intervals between hospital visits can be burdensome for patients, if the intervals are too long, then it becomes difficult to adequately evaluate the safety of the drug after it has been administered.

There is no single correct answer; each situation is unique and depends on the type of condition, the medical facility involved, and the patient. Therefore, we make decisions on a case-by-case basis, working as a team to refine our plans while balancing three critical factors: patient safety, the burden on medical staff, and data reliability.

No matter how meticulously we plan, we often have to make real-time decisions once the trial begins. To address this, we clearly define our decision-making criteria to ensure consistency across all locations. Furthermore, during the trial, we maintain a high level of vigilance by communicating closely with team members and reviewing daily data to ensure that any anomalies are spotted immediately.

I get that feeling when a trial proceeds smoothly and is completed on schedule.

Clinical trials are planned and conducted in accordance with international guidelines known as Good Clinical Practice (GCP), and are subject to notifications to and approvals from the government, as well as ethical review by participating medical institutions. While there are rules and standards that must be followed, the way a trial is conducted varies from drug to drug, and even with careful planning, unforeseen circumstances can arise.

Once a clinical trial begins, the clinical manager’s role primarily involves handling “unforeseen circumstances.” So the less I need to step in the better it is for everyone. After all, that’s the ultimate proof that patient safety is being maintained, that the clinical setting isn’t being overburdened, and that the trial is proceeding smoothly.